Clinical PET Imaging in Prostate Cancer
- 1 September 2017
- journal article
- review article
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 37 (5), 1512-1536
- https://doi.org/10.1148/rg.2017170035
Abstract
This article provides a review of the major clinically available PET tracers for the imaging of prostate cancer, describing their mechanisms of action, scan acquisition protocols, role in the clinical setting, and commonly encountered technical and imaging pearls and pitfalls. Prostate cancer is the second most common cancer in men worldwide, with a wide spectrum of biologic behavior ranging from indolent low-risk disease to highly aggressive castration-resistant prostate cancer. Conventional imaging with computed tomography, magnetic resonance imaging, and bone scintigraphy is limited for the detection of nodal disease and distant bone metastases. In addition, advances in the available therapeutic options, both localized and systemic, drive the requirement for precise diagnostic and prognostic tools to refine the individual therapeutic approach at various times in the management of patients with prostate cancer. Positron emission tomography (PET) has a rapidly evolving role in the assessment of prostate cancer, particularly in the scenario of biochemical relapse. Fluorine 18 (18F) fluorodeoxyglucose, the most widely available PET tracer, has limitations, particularly in indolent prostate cancer. In the past decade, several PET tracers with specific molecular targets have reach...This publication has 107 references indexed in Scilit:
- Utility of Choline Positron Emission Tomography/Computed Tomography for Lymph Node Involvement Identification in Intermediate- to High-risk Prostate Cancer: A Systematic Literature Review and Meta-analysisEuropean Urology, 2013
- Can we achieve a radionuclide radiation dose equal to or less than that of 99mTc-hydroxymethane diphosphonate bone scintigraphy with a low-dose 18F-sodium fluoride time-of-flight PET of diagnostic quality?Nuclear Medicine Communications, 2013
- Impact of 18F-Choline PET/CT in Prostate Cancer Patients with Biochemical Recurrence: Influence of Androgen Deprivation Therapy and Correlation with PSA KineticsJournal of Nuclear Medicine, 2013
- Prospective Evaluation of 18F-NaF and 18F-FDG PET/CT in Detection of Occult Metastatic Disease in Biochemical Recurrence of Prostate CancerClinical Nuclear Medicine, 2012
- Developing imaging strategies for castration resistant prostate cancerActa Oncologica, 2011
- 18F-fluoride PET: changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with 223Ra-chloride (Alpharadin)EJNMMI Research, 2011
- Prognostic Value of Baseline [18F] Fluorodeoxyglucose Positron Emission Tomography and 99mTc-MDP Bone Scan in Progressing Metastatic Prostate CancerClinical Cancer Research, 2010
- SNM Practice Guideline for Sodium 18F-Fluoride PET/CT Bone Scans 1.0Journal of Nuclear Medicine, 2010
- [F-18]-fluorodeoxyglucose PET-CT of the normal prostate glandAnnals of Nuclear Medicine, 2008
- An Introduction to Na18F Bone Scintigraphy: Basic Principles, Advanced Imaging Concepts, and Case ExamplesJournal of Nuclear Medicine Technology, 2007